Dr. Massimo Cristofanilli is an internationally renowned breast cancer researcher, clinician and director of the Jefferson Breast Care Center at the Kimmel Cancer Center (KCC) and Thomas Jefferson University and Hospitals. With more than 25 years of clinical, basic science and educational experience, Dr. Cristofanilli also serves as deputy director of translational research at the KCC. Prior to joining Jefferson, Dr. Cristofanilli served as chairman of the department of medical oncology at Fox Chase Cancer Center in Philadelphia and head of the center’s Inflammatory Breast Cancer Clinic. Before that, he founded and served as executive director of the Morgan Welch Inflammatory Breast Cancer Program and Clinic at The University of Texas M.D. Anderson Cancer Center in Houston, Texas.
Dr. Cristofanilli is a widely recognized leader in the translational research and treatment of inflammatory breast cancer (IBC). Moreover, he has recognized expertise in the development of novel diagnostic and prognostic markers in primary and metastatic breast cancer (MBC). His research aims to improve personalized medicine for breast cancer patients, focusing on molecular targeted agents, biomarkers and gene therapies, and bridging the gap between the bench and bedside in a more practical and smarter way. Dr. Cristofanilli is board certified by the American Board of Medical Oncology and the European Society for Medical Oncology.
Dr. Cristofanilli holds an M.D. from the University of La Sapienza in Rome, where he also completed a fellowship in medical oncology.